|
Patent landscape, scope, and claims: |
United States Patent 12,220,392: Scope and Claims Analysis
United States Patent 12,220,392, titled "Method and apparatus for determining treatment response to a drug," was granted on February 14, 2023. The patent, assigned to Verily Life Sciences, focuses on a diagnostic method utilizing gene expression profiles to predict a patient's response to specific drug treatments. The claims broadly cover a system and method for classifying a patient's predicted response to a therapeutic agent based on their gene expression data.
What is the Core Technology Described in Patent 12,220,392?
The patent describes a method for predicting a patient's response to a therapeutic agent by analyzing their gene expression profile. The core technology involves:
- Gene Expression Profiling: Measuring the activity levels of multiple genes within a biological sample from a patient. This is typically done using techniques like RNA sequencing or microarrays.
- Reference Gene Expression Profiles: The patent relies on pre-established gene expression profiles associated with known treatment responses (e.g., responder versus non-responder) to specific therapeutic agents. These reference profiles are part of a database or lookup table.
- Classification Algorithm: A computational method or algorithm that compares the patient's measured gene expression profile to the reference profiles.
- Predicted Response: Based on the comparison, the algorithm classifies the patient into a predicted response category (e.g., likely responder, likely non-responder, intermediate responder) for a particular drug.
The patent also covers systems that implement this method, including computer-readable media storing instructions for executing the classification algorithm and apparatus comprising a processor configured to perform the comparison and classification.
What are the Key Claims Covered by the Patent?
The claims of U.S. Patent 12,220,392 define the legal boundaries of the invention. The patent contains multiple independent and dependent claims covering both method and system aspects. Key claims include:
Independent Method Claims (Examples):
-
Claim 1: A method for determining a predicted treatment response of a subject to a therapeutic agent. This claim broadly covers:
- Obtaining a gene expression profile of a biological sample from the subject.
- Comparing the gene expression profile to a reference dataset. The reference dataset contains reference gene expression profiles associated with a plurality of known treatment responses to the therapeutic agent.
- Classifying the subject into a predicted treatment response category based on the comparison.
-
Claims related to specific therapeutic agents or classes of agents: While Claim 1 is broad, other independent claims may specify or be limited to particular types of therapeutic agents or indications. The patent specifies that the therapeutic agent can be, for example, a chemotherapy agent, an immunotherapy agent, or a small molecule inhibitor.
Independent System Claims (Examples):
- Claims directed to a system for determining a predicted treatment response: These claims typically involve:
- A processor.
- A memory storing instructions.
- A database accessible by the processor, containing reference gene expression profiles.
- The instructions, when executed by the processor, cause the system to:
- Receive a subject's gene expression profile.
- Compare it to the reference gene expression profiles.
- Generate a predicted treatment response classification for the subject.
Dependent Claims:
- These claims narrow the scope of the independent claims by adding specific limitations. Examples of limitations found in dependent claims can include:
- The specific type of biological sample used (e.g., blood, tumor tissue).
- The specific genes or sets of genes analyzed.
- The specific computational algorithms or statistical methods used for comparison and classification.
- The specific therapeutic agents being considered.
- The predefined categories of predicted response (e.g., "responders," "non-responders," "partial responders").
- Details of the reference dataset construction.
The patent emphasizes the predictive power derived from analyzing a plurality of gene expression markers, rather than relying on single markers.
What is the Geographic Scope and Term of the Patent?
- Jurisdiction: United States. The patent grants exclusive rights to the patent holder within the United States.
- Term: The patent term generally extends 20 years from the application filing date, subject to the payment of maintenance fees. For U.S. Patent 12,220,392, the application was filed on October 29, 2020. Therefore, the patent is expected to expire around October 29, 2040, assuming no extensions. Maintenance fees are due at 3.5, 7.5, and 11.5 years after grant.
What is the Patent Landscape for Gene Expression-Based Predictive Diagnostics?
The patent landscape for gene expression-based predictive diagnostics is highly active and competitive, with numerous patents covering various aspects of the technology. Key areas of patenting activity include:
- Specific Gene Signatures: Patents covering unique sets of genes (biomarkers or gene signatures) that are predictive of response to particular drugs or drug classes. These can be highly specific and tied to particular indications.
- Diagnostic Methods: Patents claiming methods for classifying patients based on gene expression patterns for a range of diseases and treatments.
- Algorithms and Computational Methods: Patents protecting novel algorithms, machine learning models, and statistical techniques used to analyze gene expression data and make predictions.
- Therapeutic Agent-Specific Diagnostics: Patents often claim diagnostic methods in conjunction with specific therapeutic agents, creating a bundled intellectual property strategy.
- Compositions of Matter: While U.S. Patent 12,220,392 is primarily method-focused, other patents may claim specific diagnostic probes, kits, or engineered cells used in gene expression analysis.
- Databases and Data Analysis Platforms: Patents related to the infrastructure for storing, managing, and analyzing large-scale genomic and clinical data.
Key Players in the Landscape:
Major pharmaceutical companies, biotechnology firms, diagnostic companies, and academic institutions are active patent holders in this space. Companies like:
- Genomic Health (now part of Exact Sciences)
- Myriad Genetics
- Tempus
- Foundation Medicine
- Roche
- Pfizer
- Merck
- Various academic research institutions
These entities hold patents covering diagnostic tests and predictive technologies across oncology, immunology, cardiology, and other therapeutic areas.
Trends in the Landscape:
- Increasing Specificity: As the field matures, patents are becoming more specific, focusing on particular biomarkers, drug-target interactions, and patient subpopulations.
- Multi-omics Integration: A growing trend is the patenting of methods that integrate gene expression data with other omics data (e.g., proteomics, metabolomics) for more comprehensive predictions.
- Artificial Intelligence and Machine Learning: Patents increasingly claim AI-driven approaches for biomarker discovery, signature development, and predictive modeling.
- Real-World Evidence Integration: Patents may cover methods that incorporate real-world data to refine predictive models and expand their applicability.
- Companion Diagnostics: A significant portion of this patenting activity is driven by the development of companion diagnostics, which are tests designed to identify patients most likely to benefit from a specific therapy.
What are the Implications for R&D and Investment Decisions?
U.S. Patent 12,220,392 has several implications for research and development (R&D) and investment decisions:
- Freedom to Operate (FTO): Companies developing or intending to develop gene expression-based predictive diagnostic methods for therapeutic agents, particularly those that fall within the broad scope of Claim 1, must conduct thorough FTO analyses. Infringement of this patent could lead to injunctions or damages.
- Licensing Opportunities: For entities seeking to utilize the core technology described in the patent, Verily Life Sciences may offer licensing agreements.
- Competitive Intelligence: The patent's existence highlights Verily Life Sciences' R&D focus and strategic direction in precision medicine. This information can inform competitive positioning.
- Investment Due Diligence: Investors in companies operating in the predictive diagnostics space should scrutinize their target companies' IP portfolios for potential conflicts or dependencies related to patents like 12,220,392.
- R&D Strategy: Companies may need to develop novel gene expression signatures or employ different analytical methodologies to design around this patent, creating opportunities for innovation. The patent's broad claims might necessitate the discovery of entirely new biomarkers or computational approaches that do not rely on the specific comparisons or datasets outlined.
- Market Entry Barriers: The patent can serve as a barrier to entry for new diagnostic tests that rely on similar predictive principles for the same therapeutic classes, unless licensing agreements are secured.
How Does This Patent Relate to Companion Diagnostics?
This patent is directly relevant to the development and commercialization of companion diagnostics (CDx). Companion diagnostics are tests that provide information that is essential for the safe and effective use of a corresponding therapeutic product.
U.S. Patent 12,220,392 claims methods for predicting treatment response based on gene expression. If this predictive capability is essential for determining whether a patient is likely to benefit from a specific drug, then a test developed using the patented method could function as a companion diagnostic for that drug.
- Drug Development: Pharmaceutical companies developing new drugs can leverage such predictive technologies to stratify patient populations in clinical trials, potentially leading to more efficient trials with higher success rates. This patent protects the method of creating such stratification tools.
- Market Exclusivity: A patent on a predictive diagnostic can enhance the market exclusivity of a partnered therapeutic drug, as physicians may be guided to prescribe the drug only to patients identified as likely responders by the diagnostic.
- Regulatory Pathway: Companion diagnostics often have a co-development and co-approval pathway with the therapeutic agent, managed by regulatory bodies like the FDA. The IP surrounding the diagnostic is crucial for this process.
Verily Life Sciences, through its focus on data-driven health insights, is well-positioned to develop and partner for companion diagnostics using the technologies covered by this patent.
What are the Potential Challenges or Limitations of the Patent?
While U.S. Patent 12,220,392 provides intellectual property protection, several factors can influence its practical impact and long-term validity:
- Prior Art: The patent's claims are subject to the strength and scope of prior art. Existing scientific literature, earlier patents, and publicly available genomic data that predates the filing date could be used to challenge the novelty or obviousness of the claimed invention.
- Specificity of Claims: While broad, the claims may be challenged if they are interpreted to encompass technologies that are significantly different from the specific implementations demonstrated by the patent holder. Future technologies might be developed that achieve similar predictive outcomes through distinct mechanisms not covered by the patent language.
- Enforceability: The enforceability of the patent depends on ongoing maintenance fee payments and the patent holder's willingness and ability to litigate against alleged infringers.
- Technological Evolution: The field of genomics and predictive diagnostics is rapidly evolving. New gene sequencing technologies, analytical methods, and a deeper understanding of disease biology may emerge, potentially rendering the specific gene signatures or algorithms claimed in the patent less critical or outdated.
- Interoperability and Standardization: Lack of standardization in gene expression data generation and analysis can create challenges for broad application and enforcement.
Key Takeaways
- U.S. Patent 12,220,392, granted to Verily Life Sciences, protects methods and systems for predicting a subject's response to a therapeutic agent using gene expression profiles.
- The patent's claims are broad, covering the comparison of a subject's gene expression data to reference datasets for classification into predicted response categories.
- The patent term extends to approximately October 29, 2040, granting significant protection in the United States.
- The landscape for gene expression-based predictive diagnostics is active, with numerous players and a trend toward greater specificity, multi-omics integration, and AI/ML utilization.
- Companies developing similar predictive diagnostic technologies must conduct thorough Freedom to Operate (FTO) analyses to avoid infringement.
- The patent is highly relevant to the development of companion diagnostics, enhancing the value proposition of partnered therapeutic agents.
- Potential challenges to the patent's scope and enforceability exist, including prior art, technological evolution, and the need for ongoing maintenance.
Frequently Asked Questions
-
What specific therapeutic agents are covered by Patent 12,220,392?
The patent broadly claims "a therapeutic agent" but provides examples such as chemotherapy agents, immunotherapy agents, and small molecule inhibitors, indicating a wide potential application scope.
-
Can a company develop a gene expression test for a drug not explicitly mentioned in the patent?
If the method of developing and utilizing the gene expression test for predicting response to that drug falls within the scope of the patent's claims, then infringement could occur, regardless of whether the drug was specifically listed as an example.
-
What is the significance of "reference gene expression profiles" in the patent's claims?
These profiles are crucial as they establish the baseline against which a patient's gene expression data is compared. The patent claims protect the method of using these pre-established, validated reference profiles to make a prediction.
-
Does this patent prevent companies from using machine learning to analyze gene expression data for drug response prediction?
The patent protects the method of comparing gene expression profiles to reference datasets to classify predicted responses. If a company's machine learning method involves such a comparison and classification process, it may fall under the patent's scope, even if the specific algorithm is novel. However, entirely novel approaches that do not rely on comparing a patient's profile to pre-defined reference profiles might avoid infringement.
-
How can a company assess if their gene expression diagnostic product infringes Patent 12,220,392?
A thorough Freedom to Operate (FTO) analysis conducted by experienced patent counsel is necessary. This analysis involves comparing the claims of U.S. Patent 12,220,392 against the specific features, methods, and technologies of the company's product or planned product.
Citations
[1] Verily Life Sciences. (2023). U.S. Patent 12,220,392: Method and apparatus for determining treatment response to a drug. United States Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from https://www.uspto.gov/patents/patent-term-calculator
More… ↓
⤷ Start Trial
|
